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Abstract
The commercialization of medical products at the university level is a multilayered and
challenging process. One barrier to commercialization is the difficulty of meeting Food and Drug
Administration (FDA) regulatory requirements. Regulations and standards are undoubtedly
necessary to maintain the highest product safety levels, but it creates many obstacles. This paper
will analyze how researchers involved with early-stage medical device innovation in a university
setting deal with FDA compliance issues and the implications of this engagement for innovation.
I conducted an exploratory case study of ten medical product development projects at the
Rochester Institute of Technology (RIT). Overall, I found that FDA approval pathways were
challenging for project participants to navigate without proper resources; approximately half of
the projects indicated a lack of confidence in their knowledge of and/or progress towards
meeting FDA requirements based on the resources available. I offer several suggestions
regarding how RIT and other universities can reduce barriers to innovation caused by FDA
regulation through actions, both internal and external to the university.
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Chapter I: Introduction
Introduction
Universities often foster the creation of medical devices through their support of research
and new ideas. Research centers and labs can support innovation, test theories, and devices
without the market pressures that medical device companies experience. Medical technology is
advancing quickly, as seen in the ever-growing healthcare market. Luckily, medical research in
universities can pursue ideas and theories that may have a low chance of success. Their ability to
take risks without the possibility of failure has allowed groundbreaking discoveries. When a
medical product is created or discovered that the researcher believes is worth pursuing
commercially, it moves forward for further testing, approval, and commercialization. Thus, it is
essential for any life-changing medical product created in the university setting to have adequate
commercialization compliance support. Without the proper permission, documentation, and
resources, a life-saving technology may not reach the people that need it.
A medical device falls into a category of products that is overseen by the government.
The department known for oversight within the government is the Food and Drug Administration
(FDA). They are responsible for the approval processes that allow medical products to be on the
market. Once a product is developed enough to be considered for FDA approval, the creator or
university decides whether to pursue it. The decision to pursue commercialization and approval
may seem like an easy decision; however, literature and research shows that the approval process
at this level can be challenging, expensive, and hard to navigate (Gulbranson & Audretsch,
2008).
Commercializing a medical device requires compliance with FDA regulations, which is
challenging to obtain and requires knowledge of the processes involved, as well as financial
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resources. Most recommendations for improvement to universities to help with this process
include changes to organizational structure or funding. As will be discussed in the literature
review, few papers offer any specific advice relating to regulatory compliance or any case
studies of successful models for overcoming university innovators’ regulatory barriers.
Thus, the goal of this thesis is to take a more in-depth look at how FDA regulations
impact early-stage medical device innovation projects at the university level. To do this, I
performed exploratory case studies of medical products in different stages of development at one
university. The interview questions targeted multiple aspects of their experience, such as
regulatory and compliance resources, barriers to innovation, and the university’s impact on
project success. After presenting my findings and analysis, I discuss the implications of this
research for university policy, FDA policy, and future research.
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Chapter II: Background of FDA and Definitions
Medical device innovation is a critical component in the growing field of medicine and
comprehensive care. Under the guidance of the Food and Drug Administration (FDA), the
definition of a medical device is (O. O. Affairs, 2018)
“an instrument, apparatus, implement, machine, contrivance, implant, in vitro
reagent, or other similar or related article, including a component part or
accessory which is: recognized in the official National Formulary, or the United
States Pharmacopoeia, or any supplement to them, intended for use in the
diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or
prevention of disease, in man or other animals, or intended to affect the structure
or any function of the body of man or other animals, and which does not achieve
its primary intended purposes through chemical action within or on the body of
man or other animals and which is not dependent upon being metabolized for the
achievement of any of its primary intended purposes.”
Under this definition, there are many different types of medical devices, with varying
degrees of intrusiveness or potential for harm. For example, a tongue depressor and a pacemaker
are both considered medical devices, although one is less dangerous than the other. The variance
in danger calls for a different level of regulation.
Device classifications are a way to categorize medical devices based on their risks and
the regulatory controls necessary to provide a reasonable assurance of safety and effectiveness.
(Center for Devices and Radiological Health. (2017)). Figure 1 shows the differences between
Class I, II, and III devices. The examples of products range in simplicity and class based on the
risk. The regulatory pathways are different based on the product’s class, as described in the chart
below.
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Figure 1: Types of device classifications and the differences between them (Geete, 2016).

Below are definitions of several terms that I use in this thesis. These terms explain the
FDA, different approval pathways, and the difference between a medical device and equipment.
Definitions
510(k)- is a premarket submission made to the FDA to demonstrate that the device to be
marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device
(section 513(i)(1)(A) FD&C Act) that is not subject to premarket approval.
(510(k) Premarket Notification, n.d.)
Equipment: Medical devices requiring calibration, maintenance, repair, user training, and
decommissioning – activities usually managed by clinical engineers. Medical equipment is used
for the specific purposes of diagnosis and treatment of disease or rehabilitation following disease
or injury; it can be used either alone or in combination with any accessory, consumable or other
piece of medical equipment. Medical equipment excludes implantable, disposable, or single-use
medical devices. (Medical Device – Full Definition, 2018)
FDA (Food and Drug Administration)- The Food and Drug Administration is responsible for
protecting the public health by ensuring the safety, efficacy, and security of human and
veterinary drugs, biological products, and medical devices; and by ensuring the safety of our
nation's food supply, cosmetics, and products that emit radiation. (O. O. Commissioner, 2018)
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Medical device: article, instrument, apparatus, or machine that is used in the prevention,
diagnosis, or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or
modifying the structure or function of the body for some health purpose. Typically, the purpose
of a medical device is not achieved by pharmacological, immunological, or metabolic means.
(Medical Device – Full Definition, 2018)
Predicate Device-A predicate device is a medical device that may be legally marketed in the
U.S. and used as a point of comparison for new medical devices seeking approval through
FDA’s 510(K) premarket clearance pathway. The new device must be proven to be substantially
equivalent in safety and efficacy to the predicate device in order to receive clearance.
(Predicate Device: Greenlight Guru, (n.d.)).
Pre-market Approval - is the FDA process of scientific and regulatory review to evaluate the
safety and effectiveness of Class III medical devices. Class III devices are those that support or
sustain human life, are of substantial importance in preventing impairment of human health, or
which present a potential, unreasonable risk of illness or injury.
(Premarket Approval (PMA), 2020)
Translational Research- the process of applying knowledge from basic biology and clinical
trials to techniques and tools that address critical medical needs.
(What is Translational Research?, 2017)
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Chapter III: Literature Review
The Food & Drug Administration (FDA) recently published a document that states the
main objective of regulatory entities is “helping to ensure that innovation in product
development continues, so that patients can get groundbreaking medical products while at the
same time ensuring patient safety and that harmful medical devices do not reach the market
(O.O. Commissioner, 2018).” However, a Harvard Business Review article (Minguillo &
Thelwall, 2014) describe current innovation in healthcare as “unsuccessful.” They discuss six
forces that affect the success or failure of innovation: players, funding, policy, technology,
customers, and accountability. It may not be that all of these are equally important in a university
setting. In the following sections, I will thus focus on reviewing the literature on regulatory
compliance and commercialization in universities in particular.

Commercialization in Universities
The costs associated with regulatory compliance are two of the most considerable
burdens on innovation. As stated by Herzlinger (2006), “One problem is the long investment
time needed for new drugs or therapies that require FDA approval. While venture capitalists
backing an IT start-up may be able to get their money out in two to three years, investors in a
biotech firm have to wait ten years even to find out whether a product will be approved for use.”
Innovation in universities is similarly challenged, and the difficulty of bringing a product to
market is a risk that must be weighed. Unlike private firms, however, a university's number one
goal is to research and explore new ideas, which may not include commercialization. If they are
using resources to prepare something for commercialization, it must show promise; even if there
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is a promise of success, however, the risk of failure may prevent the pursuit of
commercialization.
Despite the risks of commercialization, there has been a steady increase in the desire for
commercial outcomes from university research since the early 2000s (Ambos et al., 2008). While
this increased push for the commercialization of new technology may bring increased risks, a
healthy support system at a university can reduce this risk and help universities claim the
benefits of commercialization, such as income and increased reputation.
The promise of income and increased reputation has driven support for more
commercialization of technical innovation at universities (Ambos et al., 2008). Policymakers
also support this trend for more innovation because it increases competitiveness in the market.
They often have specific initiatives and incentives to encourage more universities to participate
in medical device innovation (Ambos et al., 2008). However, while it is mutually beneficial to
commercialize university research, it is not always easy. One issue is that different stakeholders
involved in innovation may have different motives. For example, universities have education and
research as the primary motivation, while players in the market have patient care,
competitiveness, and profit as their motivations (Marantz et al., 2010). In addition, poor
knowledge management, cultural differences, and bureaucratic struggles can hamper
commercialization efforts (Siegel et al., 2003). Pober et al. (2001) argue that contributing to the
low rate of commercialization, or translation, from universities is the fact that process can vary
from case to case and, as a result, is not straightforward or consistent. Also, the authors recognize
the need for continued research and collaboration, even following the commercialization of
technology. This type of continued support is a burden that universities cannot bear (Pober et al.,
2001).
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There is some evidence that universities can overcome these challenges and see success
in commercialization. There are many reasons for this, but most experts agree that it takes
additional structures at the university level to achieve smooth commercialization. An example of
this is the University of Michigan. They have attempted to create a model for this through their
partnership with the Wallace H. Coulter Foundation (Pienta, 2010). This partnership resulted in a
center that helps build structures and change the university culture to better support collaboration
between the university faculty and professionals in the medical field. As explained on the
Coulter Translational Research Partnership Program website, the center is described as follows
(About the Program, 2016):
The U-M Coulter Translational Research Partnership Program is a commercialization
fund that seeks to accelerate the development of university technologies into new
products to improve health care. The program funds 5-7 projects per year for an average
of over $100,000 each. Each project must involve a collaboration between UM faculty
from any college of engineering department and a practicing clinician from a clinical
department. Each project aims to generate a new medical device, surgical tool, diagnostic
assay or other biomedical tool and is mentored by a team of industry experts to guide
projects to the point of start-up, partnering with industry, and/or follow-on funding.

Minguillo and Thelwall (2014) found that these new infrastructures appear to have the
most success in having positive interactions between universities and the market. Another type of
enabling structure is a proof-of-concept center. University researchers struggle to obtain funding
during the early stages, and a proof-of-concept center bridges that gap by providing researchers
with appropriate funding (Gulbranson & Audretsch, 2008). With that said, creating these new
structures takes a certain amount of time, resources, and effort that many universities simply
cannot afford.
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Regulatory Compliance
The overall success of the product can not be achieved without compliance with the FDA
and other regulatory bodies. Compliance with the FDA is challenging and requires both
knowledge of the regulatory process and a high amount of resources. This leads to more
commercialization success at the large company level than the university level (Schwartz &
Macomber, 2017). As just discussed, most recommendations of improvement to universities
include changes to organizational structure and/or funding. Noticeably absent from the literature,
however, was any mention of specific recommendations relating to assistance with regulations or
the compliance of devices.
Medical devices vary significantly in their use, risk, complexity, and other characteristics.
Understanding how individuals at universities handle the burden of compliance for such a range
of products should be researched and understood. It was surprisingly difficult to find
information detailing success case studies or a model for overcoming regulatory body barriers
for university innovators. Throughout the literature review, there were examples of successful
medical innovations, yet not nearly enough recommendations for becoming successful in the
stages where compliance is necessary.
Thus, while the literature discusses how universities have found success in medical
device innovative efforts through culture change, increased funding, and new structures, it is
unclear how these universities have achieved regulatory compliance success. It is evident that a
university must show a genuine interest in growing the success of innovation in order to grow
their program. However, what they need to do to provide support for regulatory compliance
remains unclear. The potential of university medical research could be endless, but the lack of
understanding in compliance processes is holding back many institutions. Therefore, the gap of
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information found in this literature review shows that universities need a greater understanding
of the regulatory barriers to commercializing their medical device innovations.

Research Question:
The literature review addresses commercialization in universities and regulatory
compliance. As shown in the literature review, commercialization is an increasingly common
goal for university-based medical device innovation. The literature review shows a large gap in
our knowledge of how regulatory compliance impacts medical device innovation at the
university level and how universities can help with respect to compliance issues. Thus, in this
thesis, I ask: How does FDA regulation impact early-stage medical device innovation projects
at the university level? In particular, three specific sub-questions are looked at:
1. What sources of information did the project use to learn about compliance
standards for FDA regulations?
2. What barriers to innovation have the project owners faced with regard to
regulatory compliance and how did they overcome these barriers?
3. How do the information sources and barriers impact the product design and
ultimate project success?
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Chapter IV: Methodology
Data Collection
Access was a deciding factor in choosing to focus on the RIT population’s medical
products and research. It would have been challenging to contact other universities to access
their staff, students, and research while keeping anonymity. Remaining within RIT gave a more
focused study and decreased the possibility of delays or issues. Also, RIT is an exciting
institution to analyze because it is very active in medical innovation. Still, it does not have an
associated medical school to conduct trials at or implement the innovation.
Snowball sampling was the method used to recruit possible products (Johnson, 2014). I
reached out to past and present department heads in the Kate Gleason School of Engineering to
create a list of potential research contacts. The potential products needed to meet specific
requirements to participate in the study. The products needed to be created on the Rochester
Institute of Technology campus, be classified as a medical product and be recognized by RIT as
a university project. The products were chosen to represent a wide range of innovation types.
Once the devices were selected, the contacts received an email asking for participation in the
study; all contacts responded and agreed to participate.
After connecting with all contacts, selecting ten medical device projects ranging from
beginning stages to commercialization took place. All products and subjects remain confidential
to keep any intellectual property concerns to a minimum. Due to the COVID-19 lockdown and
quarantine, the interviews could not be held in person and instead were on ZOOM during the
Spring and Summer of 2020. All of the meetings were recorded and placed in a private drive
with the interviewees’ consent. The meetings were transcribed word by word to allow for direct
quote use.
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After gathering information about each project, I created tables to assign a coded number
and compare their basic details such as device class, owner, and function. Doing so kept the
anonymity of the products while also keeping the product list consistent. After the general
product details were analyzed, I created tables that contained more specific information to
compare the resources used for compliance and regulatory data. The resources varied based on
the type of product. The transcripts were analyzed to pull out direct quotes of the barriers faced
by project owners. The most prevalent barriers described in the transcripts were examined and
further analyzed. Lastly, the impact of university policy and regulation was analyzed for the
specific project types and explained further.
Due to the patterns seen across the projects, I decided to split the data and tables apart
into three sections. The three sections are labeled Sponsored Projects, Research Projects, and
Individual Projects, to be defined later. After dividing the sections and splitting the tables, I also
created three subheadings for each section. The three subheadings for each product are labeled as
Information Resources, Primary Barriers Encountered, and Impacts to organize the findings.
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Chapter IV: Analysis of Data
Overview of Projects
Table 1 shows the ten products chosen for the thesis. For anonymity, the products
received a corresponding number used throughout the analysis and a basic description. The basic
description is an indication of the complexity and risk of the product. For example, an
implantable device is riskier than a modeling device. The risks described in the class column
correlate with the basic description and can aid in understanding the product. The goal of the
project states the end result the owner intends to reach. Commercialization means the project was
intended to be commercialized from conception. Research with intent to market means the
owner’s primary goal is basic research but is willing to commercialize with a successful product.
Lastly, basic research means there is no intent to commercialize the product.
Table 1: Description of the type of product, product FDA class, and the goal of the
product project. See definition sections for explanation of the categories.
Product Type of Product Class
Basic Description
Goal of Project
1

Device

I

External health monitoring system

Commercialization

2

Device

III

Implantable device

Research with intent to market

3

Equipment

I

Assistive equipment

Commercialization

4

Equipment

I

Modeling device

Basic research

5

Device

I

Assistive equipment

Commercialization

6

Equipment

I

Biological prototyping device

Commercialization

Device

I or II

Investigative Autonomical Tool
Used During Physical Exams

Commercialization
Basic research

7
8

Device

III

Technological Advancement for
Assistive Devices

9

Device

III

Life-Sustaining Internal Device

Research with intent to market

10

Device

I or II

Personal Protective Gear

Commercialization
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At least half of the products are Class I products, the lowest risk class, while three of the
products were Class III. I also classified the projects as being focused on either devices or
equipment to give the reader a better understanding of their function. A device is used in the
prevention, diagnosis, or treatment of illness or disease or for detecting, measuring, restoring,
correcting, or modifying the structure or function of the body for some health purpose. In
contrast, equipment is used for activities usually managed by clinical engineers. Medical
equipment is used for the specific purposes of diagnosis and treatment of disease or rehabilitation
following disease or injury (Medical Device – Full Definition, 2018). Out of the ten products,
seven are classified as devices, while the other three are equipment.
As seen in Table 2, the product’s origin is an indicator of the type of support it has from
the university. A research product originates in a research lab. The university, along with
external research grants, financially supports the project and RIT staff are the project leaders.
Sponsored Projects originate from clients internal or external to the university and are run by
students; while the university does not fund them, students can use available resources at RIT.
Participants in Research and Sponsored Projects would acknowledge the role the university
played in the case of a successful product. Lastly, Individual Projects are those recognized by
RIT but do not use RIT funds and would not recognize RIT as a stakeholder of the project. The
findings in Table 1 and 2 show that all Class I, or the lowest risk projects, fell under Sponsored
Projects and were run by students, while three out of the four Research Projects were Class III.
Three of the Research Projects were done in collaboration with external companies.
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Table 2: Range of products chosen based on origin, collaborator, and project owner.
Product

Origin

Collaborator

Project Owner

1

Research Project

Company

Staff

2

Research Project

Company

Staff

3

Sponsored Project

N/A

Student

4

Sponsored Project

N/A

Student

5

Sponsored Project

N/A

Student

6

Sponsored Project

N/A

Student

7

Sponsored Project

N/A

Student

8

Research Project

N/A

Staff

9

Research Project

Company

Staff

10

Individual Project

N/A

Student

Research Projects
As stated earlier, the research products exist in a research lab and run by RIT staff. All
products in this section are devices that are used directly by medical staff (i.e., pacemakers,
artificial hips) rather than equipment that is often managed by engineers (i.e., patient monitors).
This section will look at the resources for compliance, barriers experienced by project owners,
and the impact of these resources and barriers on ultimate product design and project success.

Information Resources
The design process for a typical medical product begins with an idea and ends with
commercialization. To create a successful medical product, each stage of innovation relies on
knowledge gained from various resources. Without knowing the proper design and safety
requirements, a medical device can not reach the market and be successful. Based on its device
class, each product needs to meet different design and testing criteria for the chosen FDA
pathway. The impact of good or bad information sources can affect the outcome of the ability of
a product to comply with regulatory requirements, as well as choices in the design itself. Low-
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quality information is more likely to harm the product, while a high-quality source will help the
product advance through the innovation process. Common compliance information needs include
device classifications, approval pathways, design criteria, necessary documentation, and testing
requirements documents.
Table 3 details the resources used to gather information on regulatory standards in the
Research Projects. Six primary sources provided the information on FDA guidelines for
products. These sources are design standards (such as ISO, IEEE), expert consults, other
established companies, customers, a general internet search, and looking at existing technology.
A consistent theme in the interviews was how information about regulatory requirements for a
specific product was difficult to come by. Across the ten devices, most researchers obtained
their knowledge through different sources.

Table 3: Resources used to gather the FDA process and design criteria for research products.
Design
Expert
Existing
Product Origin of Support Standards Consult Company Customer Internet Technology
1

RIT/ Company

2

NIH/RIT/ Company

8

Company/ NIH/RIT

9

RIT

X

X

X

X

X

X

X
X

X
X

X

All four of the Research Projects, headed by RIT staff, were able to connect with experts
or have a relationship with companies. A range of other resources was used as well, although not
the same extent as experts and companies. Having information sources backed by experienced
companies and institutions outside of RIT provided an adequate level of confidence in the quality
of information and expertise. The experts seem to be available through RIT connections, as well
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as external connections gained through the personal researcher’s network developed over their
career. The experts used by the researchers are not shared across others in the university. There
is typically a high degree of confidence about the quality of data through expert consultants and
companies with prior experience. Thus, these projects have access to reliable information on
FDA compliance.
Product 1 is a low-risk device, as shown in Table 1. The owner of the device believes the
device has the potential to be successful and is pushing the product to market. The owner of the
project started a company to support any of the product needs. This company is specifically
dedicated to the success and commercialization of the product. The interviewee stated that “the
company is taking it through the FDA. That is expensive to do, and there is expertise that is
required to do it. The company has an FDA consultant who understands how to go about doing
those filings with the FDA.”
Translational research, as defined previously, is specifically designed to improve health
outcomes. It uses an integrated team of experts who are focused on translating useful information
from laboratories to doctors’ offices and hospitals and is a “bench to bedside” bridge (“What is
Translational Research?,” 2017). The translational pathway of research to commercialization is
not common at RIT; with limited past translated products to use as a model, innovation at RIT is
challenging. The interviewee believes going through the FDA approval process is extremely
uncommon on campus. The interviews indicated that this lack of experience could harm the
translational process. The limited knowledge of the university showcases the lack of resources
available to entrepreneurs, engineers, and collaborators to commercialize innovation. Luckily,
the company created to assist the product has hired experts, and the product will have the
resources needed to move forward.
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Product 2, a Class III device, is still being used on animals, which limits the involvement
of the FDA. When the researcher plans to move forward, their path will include collaboration
with a larger company to assist in human testing and gaining FDA approval. The cost and time
associated with testing a Class III device can be overwhelming for a university with limited
experience. The interviewee believed that “most academics do not have any experience with that
[FDA testing and approval]. It is very different from the majority of what we do for our research
and how we write proposals. Usually, people would partner with companies.” Based on the
researcher's experience, collaboration with a larger company seems to be the most efficient way
for a Class III technology to be translated.
Product 8’s project leaders have possible plans to commercialize their Class II product.
The progress of the product has not yet reached a point that requires the attention of the FDA for
compliance. However, early consideration of FDA requirements could help avoid problems later
on. Understanding different approval pathways and compliance standards could lead to changes
that pay off later. The researcher already has plans to work with a multinational company for
further testing and translation of the product once the product is ready for an FDA pathway. This
company has experience with similar products and believes this is the best way to advance.
Product 9, a Class III device, is not going to be commercialized. Their project was a
response to the COVID-19 pandemic, and their efforts proved to be fruitless as they did not have
the resources to continue. Before the COVID-19 pandemic led to a partial shut down of
university activities, the project members explored the FDA approval process through selfresearch and outside collaborators. The interviewee explained, “the problems that we were
tackling there were not any regulations that would have hindered us, and if there were any
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regulations, we were letting our partners make those decisions.” The resources used for approval
of this project would not have come from the university but outside consultants.
In sum, three out of the four Research Projects planned to use the help of companies, and
the other used expert consultation through external collaborations. The Research Projects
gathered information from additional sources, such as companies and consultants. Collaboration
with companies has extreme advantages, such as knowledge, staff, and funding. Working with
the company gives a researcher the freedom to continue working on their work at the university,
yet both parties can benefit. Based on the research, there are few currently known disadvantages
for company collaboration. For university innovators with little experience, a company can be
the difference between success or failure.

Experienced Barriers
Lack of Knowledge
At RIT, researchers are responsible for many of the products that may result in a
commercial product, but they can also experience barriers that stunt their possible successes.
There are many things about regulation and compliance that researchers don’t know and can not
learn at the university. Luckily, the researchers in this study tended to have enough resources
outside of the university to overcome this barrier.
One of the specific barriers experienced by the researchers was a lack of knowledge of
documentation procedures. The FDA requires not only documentation for the final product, but
also the process of developing the product. This can include design, test results, and other
process steps. However, there is little to no standard documentation process to assist researchers
in commercialization. A researcher stated,
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“We don’t have documented procedures that define the way we do product development.
We don’t do a good job with documenting the design. We don’t do a good job with
documenting the way that we produce it. We don’t have procedures for the way that you
make them, and we don’t have procedures for everything you test in a quality system
where we take all of that data, and it’s documented for every device. What that means is,
if I produce the devices out of the university and we get all these great results from this
study, which is a five-year study, I can’t actually use it to submit to the FDA. We have to
do it again. It still has value, because it can show with technology like this, you can
reduce hospitalization rates. You just can’t use that data to file with the FDA to be able
to claim that you can use it to achieve that result.”
This statement shows the importance of understanding the required documentation process. This
lack of knowledge can cause a great deal of rework, and this particular researcher needed to start
a company to redo some of the development work in order to create the necessary
documentation.

Lack of Resources
To overcome their minimal expertise on regulatory compliance, the Research Projects
also needed human and financial resources. University settings are helpful in research; however,
they do not provide the resources a company does to further the product on the path to
commercialization. To overcome this barrier, researchers with a marketable product may create a
company. An interviewee explained the added that the money and expertise a company brings
may be necessary for success. Hiring full-time experts that can be devoted to the project is
beneficial. This researcher explained how they “started a company to commercialize it. That
company is taking it through the FDA. That is expensive to do, and there is expertise that is
required to do it. The company has an FDA consultant who understands how to go about doing
those filings with the FDA.” Without specialized FDA experts at the university, this researcher
pursued another way to gain advice and help.
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Although starting a company seems like the best way to pursue commercialization and
approval, it can be a challenging path with hefty expenses. A researcher explained that they felt
there was no other way to bring their product to market other than partnering with a company or
starting one. He explained that starting a company is “really expensive, and we don’t have the
NIH funding to help you get through that process, but most academics do not have any
experience with that. It’s very different from the majority of what we do for our research and the
way that we write proposals. Usually, people would partner with companies.”
Partnering with companies can be a mutually beneficial path as long as both parties have
enough confidence in each other in order for the collaboration to work. Most companies will not
risk resources for a product without a proven need or a high possibility of success. There is also
no specified process for collaborating with a company and it can be challenging for a researcher
that does not have experience building this type of relationship. Other researchers are lucky
enough to have personal connections to information sources such as other universities,
companies, or consultants. One researcher explained how they gathered information and where
they got it from in the following quote.
Well in our case, we did have some input and insight from people that have medical
device experience in developing and working with regulatory agencies so people that
have worked in industry for a while, so I would classify them as consultants. In some
cases, one of the consultants was unpaid and a personal connection. Another case, the U
of R actually has a translational research center you may know of. So they actually have
staff that are there to help you with that. So they are able to point us to some documents,
but in the end we had to interpret them ourselves because they were not experts in exactly
what we wanted to do. But it did give us some direction in where we wanted to go.”

A large issue encountered by researchers is a lack of resources and funding. A lab usually
employs or allows students to work in a lab for financial compensation or experience. Students in
research labs looking to gain experience in their designated field usually perform the tedious
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tasks of documentation and other clerical tasks for FDA approval. These tasks are often seen as
busy work and not given the proper care or attention they should. Even with the research
assistants able to do little work on documentation, it is nowhere near the necessary amount
needed for FDA approval submissions. Lack of funds and resources leads to products not
reaching their full potential or using an external company. The lack of funds for one project
during COVID-19 halted their progress. As explained by one person: “as our supplies dwindled,
the financial security of the university came into play and so we weren't going to be able to
purchase tens of thousands of dollars of material.” In this case, the lab's work ended due to the
considerable lack of resources.

Lack of Motivation
Another barrier might be the researchers’ own motivation to commercialize the
technology. Some researchers are not interested in commercializing the product on their own but
are open to building a device with the potential for commercialization to be pursued by a
company collaboration. These researchers aim to prove that the product is helpful and useful in
the medical field; however, they are not interested in anything more. A researcher's main
objective is to discover the technology, not sell or approve products. One creator at the university
explained his feelings on discovery and innovation as, “when it comes to regulation, makers in
general don't pay attention to it. Because they're not thinking about commercializing it, or they're
not going to be using it on people. So the safety’s not safe there.” One person indicated that the
developer wants the product to fulfill its potential but is not interested in the process to get it
further than a lab. They said, “that’s one where we right now are trying to follow some of these
ASTM standards to make sure whatever data we do collect would be meaningful to someone that
then wanted to actually spin it out or scale it up.”
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Impact
A common consideration for owners of the Research Projects was how to be impacted the
least by compliance and regulation, as rework and wasting time is not desirable. Three out of
four device projects collaborated with companies that help to optimize the commercialization
process. The interviewees mentioned changing their devices to avoid setbacks. Based on the
expertise of collaborators and the possibility of changing the function of a device, work can be
done to lessen the impact of regulation and compliance. Some interviewed also believed that the
timing of their consideration of FDA regulations for regulation had an impact on the ultimate
product design. In some instances, early compliance consideration can change the entire project.
When talking to the interviewee of Project 1, he began describing the effect of the FDA
regulations as, “It made us decide not to do a [certain product function].” He went on to say, “At
the early stages of design, we made that decision so that it would relieve the burden on us to
begin doing human subject testing.” With this change, the project would use a cheaper and
quicker FDA approval pathway when the time comes to apply for FDA approval.
Alternatively, sometimes a necessary design change may not happen because
consideration for compliance did not occur until the project’s end. A product could miss
compliance criteria or lack the necessary testing. Another interviewee said, “What that means is,
if I produce the devices out of the university and we get all these great results from this study,
which is a five-year study, I can’t actually use it to submit to the FDA.” It is important to note
that it is not always the owner’s fault, but it points to the need for a better understanding of the
best time to consider compliance and regulation.
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Sponsored Projects
As stated earlier, Sponsored Projects are run by students, not funded directly by RIT, and
use RIT resources. This section will continue to look at the resources for compliance, barriers
experienced by project owners, and the impact each had on the sponsored products.

Information Resources
Products 3, 4, 5, 6, and 7 were Sponsored Projects and relied on a student team-based
approach to development. Within the teams, specific members were responsible for gathering the
compliance information.
Table 4: This table showcases the different resources used by the students at RIT.
Design Standards/
Expert
Personal
Product
Sponsor
Consult
Knowledge
Customer Internet
3

X

4
5

X

X

X
X

X

X

X

6

X

7

X

X

X

For these projects, most of the information resources were found through internet
searches. The product 3 team, working on Class I equipment, first used an internet search to
acquire information and had difficulty finding the resources they needed on the internet. They
used what little resources they could find. Their precedence for FDA approval can help design
new products; however, the student must understand the purpose. Other resources at RIT were
also unhelpful. Finally, they turned to another university they had a connection with. It took one
team member three different attempts to find the information needed to understand the product’s
requirements.
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A team member working on Product 3 recalled, “I talked to a professor that said RIT
lacks at helping students with documentation, research, and knowing what to do. So I scheduled
a meeting with our customer, who is a medical director at another college, and she got me into
contact with the regulatory director at another university, and he gave guidance on the clearances
we needed.” A team member for Product 4, a Class I equipment, did their own research. He
concluded that due to the nature of their product, no testing or FDA concerns were necessary.
The team member drew the conclusion from online research but did not consult any expert or
contact the FDA to corroborate this conclusion. Their lack of assurance from expert sources may
be a risk when furthering the device for commercialization.
Product 5, a Class I device, used a single team member to do the FDA compliance
research for the project. The search resulted in vague results. Their information was based
mainly on design standards and predicate devices, which are used as a point of comparison for
new medical devices seeking approval (“Predicate Device: Greenlight Guru,” n.d.). The team
guide, a faculty member appointed to assist in any issues, was unsure how to help with the
search. The team relied solely on the internet and still does not believe their results were
thorough enough to be confident in receiving FDA approval.
Product 7, a Class I or II device, relied heavily on internet research and predicate device
standards. The standards for many predicate devices did not help the team, as their product
design was to be completely different from previous products; their internet research resulted in
generic results that needed interpretation. The team decided to follow some International
Organization for Standardization (ISO) standards for the materials used in the product and then
rely on mechanical testing for safety standards.
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All of the students relied on the internet for information. As mentioned earlier, internet
information, such as information on device class, can be interpreted in many ways and may set a
project up with incorrect information. Students also looked to international design standards for
their product because they needed indisputable and unquestionable sources. The incentive to
commercialize may be lower for these products because uncertainty in the path to compliance
makes it a riskier endeavor. Without expert consultation, no one could be sure the information
the students gathered was 100% correct. Lastly, the personal knowledge the students used was
more often intuition-based than experience-based. This is not promising for compliance
standards and moving forward with FDA approval. The only student with an expert consultation
used her personal connections for the information, which all students do not have access to.

Primary Barriers Encountered
Lack of Knowledge
For this group of products, there were several barriers mentioned by project owners.
Some of these issues were caused by a lack of knowledge. It was usually a student's first time
navigating the FDA compliance information; therefore, the students were unsure how to proceed
with much of the investigation. The students also must interpret all findings on the internet, and
without previous knowledge, they may consider inaccurate or incomplete information to be true.
For example, one of the students stated, “For regulatory information, I did most of the research.
There were ISO standards I found, however, nobody told me whether I needed that. It was hard
to find, so I put a lot of time into it. There were ASTM, ISO, and IEEE standards, and I found the
device class and used it as a guideline knowing in the future it would be able to pass FDA
approvals.” The student used information recognized for engineering practices; however, it is not
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explicitly for medical devices. There is much that goes into the safety and efficacy of a project
besides the mechanical properties. Based on the lack of information for the student, they used the
best compliance suggestions available.
As another example, until the final product design is near completion, it may be unknown
whether the device can use an existing predicate and therefore be exempt from a pre-market
approval process and qualified for a 501(k). This happened for Project 7. One student stated that,
“We believed we could use a 501(k) device pathway so we put in much time learning about the
process and understanding predicate devices. By the end of our design process, we found out that
the device would need to go through a different process.” Without a knowledgeable consultant,
the team’s assumption caused extra work and wasted time. This mistake could have been
avoided with more understanding of the process. It is unclear whether the student prematurely
chose a pathway and needed to change the product after initial designs or if the student
misunderstood the FDA requirements. Either way, the student was confused about the process,
and prematurely chose a pathway that caused unnecessary rework time and cost.
With many companies having departments committed explicitly to stay up to date with
FDA regulations, it is no surprise that students would have trouble navigating the changes in
regulatory standards that frequently occur. With so much information and change, it is
challenging for an inexperienced FDA regulation interpreter to stay up to date with everchanging
FDA policies.

Lack of Guidance
At RIT, students typically research FDA pathways in classroom settings before creating
any product prototypes to help with design requirements. Without experience and a full
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understanding of the regulatory field, students can make incorrect choices for their product
design. It is easy to decide an approval pathway before the product is finished; however, this
ultimately may not be the best pathway. As seen previously in product 1, experts suggested
changing the product slightly to avoid a more stringent pathway. However, the experience and
knowledge used to make that decision are not available for all students. Even with specific
faculty and guides, the lack of experts trained on FDA matters has an effect. A student explained,
“Our guide was trying to understand the process with us and at times interpreted the information
wrong.”
Some students used personal resources to further their product because they could not
find the necessary help at RIT. The student could not locate staff knowledgeable enough on their
needs and had trouble finding the internet information. When asked if the campus resource was
helpful, the student replied, “No, they were not helpful.” When asked if they could use the
established design standards as a means for knowing if they would pass FDA approval, the
student replied, “I don't know if we would. I don't think this would need to go through the FDA,
maybe a predicate device. It could also be a Class I. I think further iterations would be.” The
design of this product did not change much throughout the development process. It can be
assumed that the uncertainty stems from a lack of knowledge rather than any design changes.
This answer shows a large amount of uncertainty in their work. Handing a product with that
much uncertainty off to be commercialized can cause a bad reputation for the university.

Impact
Most impacts of the resources and barriers were negative for Sponsored Projects. As
noted previously, the students’ resources were not sufficient, and they often did not understand
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compliance standards. Many students turned to international design standards for guidance,
which had a small impact on their designs. Product 4 and 8 chose their product material based on
design standards. The design standards helped guide the students but did not impact their design
significantly.
The Sponsored Projects all waited considerably longer in the design process than the
Research Projects to consider compliance, but not many students would know that. It is
concluded that a sooner consideration with expert experience and knowledge can help save time
and money. With proper guidance and resources from the university, the product’s impact can be
improved rather than minimized. The lack of resources kept the students uninformed on how
specific product characteristics can alter the FDA pathways that they choose.

Individual Project
As stated earlier, Individual Projects are recognized by RIT, not funded directly by RIT,
and RIT is not a stakeholder of the project.

Information Resources
As shown in Table 5, the Individual Project did not rely on RIT help and used the
internet, the FDA hotline, and international design standards. The outreach to the FDA proved to
be subjective due to multiple responses with conflicting information. As mentioned earlier, one
FDA worker said the device would be Class I, while the other said it would be Class II because it
related to a deadly disease.
Table 5: Resources used by the Individual Project for compliance and design requirements.
Product Design Standards Expert Consult Personal Knowledge Customer Internet
10

X

X

X
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Product 10, an individual product founded at RIT, could fall under a Class I or II
category. This product began during the beginning of the COVID-19 pandemic with a vision of
improving an existing product rather than creating a new device. Navigating the approval process
during the pandemic proved to be difficult for the team. They found that new exemptions and
changes to speed approvals caused even more confusion. The interviewee explained how they
“spent countless hours on the phone with them [the FDA] trying to figure out what classification
our device is and received a different answer every time. They weren’t able to give us the
answers we needed. So, in general, it has been a pretty difficult process, maneuvering the FDA.”
The fast-paced nature of commercializing during a pandemic was not something the team could
find resources on and at times felt lost in a sea of contradicting information.

Primary Barriers Encountered
Only one of the products within this case study is considered an individual product.
While an RIT student is conducting it, it is not being funded or located on campus. The student
has encountered many difficulties with finding the necessary information and funding. The
student is self-employed, thus responsible for obtaining both. Their experience with finding
approval information has not been comfortable, and they have gone as far as contacting the FDA
directly. However, the information received from each consultant has slight irregularities and is
subjective. To tackle funding, the student had to improvise and use the resources they already
had for manufacturing. The student stated, “Basically, where we left off is that we did not have
the necessary funds for a huge down payment for mass manufacturing, so we kind of made our
own on the side, we printed them, we would rather have them injection molded, but we printed
them cause that is what we can do.” The student knew that the cheaper way was not the best, but
due to the lack of support and using personal resources, they did the best they could.
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Impact
The resources and barriers of this project did not have a physical impact on the
equipment. However, it did impact the timeline of the project. The uncertainty about resources
and difficulties communicating with the FDA caused a slower timeline for the project. In this
case, time wasted meant money wasted, and it eventually slowed the project to a halt, missing a
window of opportunity for commercialization.
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Chapter VI: Discussion and Conclusion
Analysis of Findings
This study highlighted the difficulties faced by innovators at multiple levels at the
Rochester Institute of Technology. The analysis shows the current resources and supports the
projects have is insufficient in overcoming the barriers and issues they face. Lastly, compliance
is daunting and may push researchers away from considering their device for the market. With
proper help, the success rate could increase and limit the struggles faced by students and
researchers. Luckily, some researchers could collaborate with companies, experts, and other
helpful resources. On the other hand, students participating in innovation at RIT lacked
knowledge and resources to acquire this knowledge advance, e missing out on potential success
for their project and the Institute. These limitations slowed project progress, led to incorrect
information, and hampered project success. A consistent theme in the interviews was how
information about regulatory requirements for a specific product was difficult to come by.

Figure 2: A comparison of project types and a pathway to their confidence in compliance.
The first research question to be answered is, “What sources of information did the
project have to learn about compliance standards for FDA regulations?” Across the ten devices,
most researchers obtained their knowledge through entirely different sources, and not all of these
sources were easy to use or reliable. As shown in Figure 2, the primary information source for

37

Sponsored and Individual Projects was the internet, while Research Projects have access to
company experts. Based on the information pulled from the interviews, it can be concluded that
the quality of information depended on the source. The research showed that no projects could
complete innovation to market processes using only RIT resources. Similarly, the lack of
resources and funding for compliance and approval efforts was a central theme across the
projects. The access to company collaboration and resources gave owners high confidence in
compliance. Thus, there seems to be a strong correlation between the origin of the project and the
strength of their resources. The Research Projects had external resources and experts while
Sponsored, and Individual Projects used more internet and personal knowledge. This may be
because support for Sponsored Projects tends to come from customers with small fixed budgets.
Although it is clear that using external resources, such as those found in an established
company, has advantages, these resources are not always easy to attain. The external connections
used for the Research Projects are gained throughout the researcher’s experience, and typically
not through RIT. The experts used by the researchers are not advertised to the entire university
body. It is important to keep in mind, as stated in the literature review, there is a need for
continued research and collaboration, even following the commercialization of technology. This
type of continued support is a burden that universities cannot bear (Pober et al., 2001).
As expected, all of the projects faced barriers related to regulatory compliance; however,
the issues were different based on the type of project. The Individual and Sponsored Projects had
issues that related to lack of knowledge and a lack of resources to attain this knowledge, which
led to confusion, frustration and misinformation. On the other hand, while Research Projects had
problems related to knowledge, such as FDA documentation requirements, and lack of university
resources to acquire this knowledge, some projects were able to overcome this barrier through
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external collaboration. It was clear from interviews that different resources available to the
projects affected the type of issues they experienced.
Lastly, perceptions of regulatory requirements did impact the product design choices.
Multiple projects in the research and sponsored category changed their designs based on the
resources and barriers. The Sponsored Projects had smaller tweaks based on design standards,
while one Research Project changed a main function to avoid a more stringent FDA pathway.
The cases highlight the importance of when a project starts considering FDA compliance.
On one hand, the earlier you start considering this, the less rework you might require based on
regulation and the fewer unexpected speedbumps. This is particularly important for regulatory
requirements on product development documentation. I found, however, that some researchers
are not interested in commercializing the product on their own and therefore do not consider
FDA approval or the necessary documentation. For these products, it was only thought of after
the product showed commercial promise. Thus, much of the testing and documentation needed
rework. These researchers aim to prove that the product is helpful and useful in the medical field
and it will be the partner company’s job to carry it to market.
On the other hand, this points to a paradox when it comes to timing consideration. As
seen with students, there can be issues with early consideration of regulation if the information is
incorrect or is interpreted incorrectly. This has the potential to lead the project down a specific
design path that might prove to be the wrong one. This points to the importance of access to
expert consultation early in the innovation process.
In conclusion, the investigative nature of the study found many instances of innovation at
the Rochester Institute of Technology. However, none of the projects analyzed in this study
could complete the commercialization process using RIT resources alone, and some faced
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significant barriers. The origin of the project directly relates to the strength of the resources that
are available for that project. Those products with little access to external expert’s struggle. The
study concluded there was a significant gap in a university setting between FDA compliance, the
commercialization process, and the resources and expertise needed to achieve it.
Limitations
There are a number of limitations of this study. The limited amount of medical device
innovation at RIT narrowed the sample size of the research. Only one person from each project
team was interviewed, which may have restricted the experiences and information about each
project. The lack of access to project details and only relying on interviews for project
information may cause discrepancies in the data.
The snowball sampling technique caused a nonrandom selection of each project
(Johnson, 2014). Only ten projects were chosen, and they may have related experiences based on
the sampling technique. I also did not talk to administrators at RIT that might know of available
projects that were not taken advantage of.
Implications
Implications for Research
As noted in the literature review, there is a need to address regulatory concerns more
specifically on the research that looks at commercialization of university research. This study
shows that this is, indeed, a barrier to commercialization. Future research can address the
limitations of this study with large and less exploratory research on the topic. Increasing the
sample size, the number of individuals interviewed, and the number and type of universities
investigated are a number of ways future research can build on this study. For example, other
universities, such as the University of Michigan (UM), have a different culture around medical
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innovation. UM has an entire program to help innovators, which contributes to their supportive
culture and big success. Conducting a comparative study would be very interesting.

Implications for University Policy
If RIT (and other universities) are genuinely interested in commercializing medical
devices, they need to provide better support for the regulatory compliance aspect of medical
device innovation. This support can take multiple forms. With some students forced to find
experts at another university, an open channel with other universities would allow innovators to
gain access to information not available at RIT.
RIT currently runs a Personalized Healthcare Technology program that aims to “integrate
interdisciplinary research” to solve medical problems (Personalized Healthcare Technology,
n.d.). However, this program does not solve or mention the issues associated with regulation or
compliance efforts, as analyzed in this thesis.
Education and training for those involved in innovation could go a long way for the
university. There is currently a lack of knowledge or where to look elsewhere for it. There are
some researchers on campus with experience in compliance that could help students relying on
personal knowledge and the internet. However, there are not enough people with the amount of
knowledge needed. Specifically, for students that do not have access to external resources or
companies, a full-time regulatory expert would be useful. The expert could also aid faculty and,
thus, would significantly decrease rework times and facilitate innovation efforts.
Alternatively, the university could help facilitate external networks with regulatory
experts. Teaming up with a company or expert as soon as the product shows promise would
relieve some barriers and extra rework. This type of network could also help medical device
innovators at the university to share their experience with each other on topics such as
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documentation, testing, and other difficulties. With stronger documentation of observations
regarding the regulatory and compliance process, a network can educate other innovators in the
same scenario. Previously, I mentioned how the Wallace H. Coulter Foundation at the
University of Michigan was created to give students and staff the help needed to commercialize.
This could be a model for other universities, including RIT, could use to build structures and
change the culture to support collaboration between the university faculty and professionals in
the medical field (Pienta, 2010). This would require extra support at the university level.
Implications for FDA Policy
FDA policy can do more to explicitly address the barriers for university innovators, such
as lack of knowledge, lack of guidance, and lack of motivation. FDA policy has proven to be
difficult to navigate for many I interviewed. From the novice’s perspective, the FDA does not
have clear-cut instructions on how to achieve compliance works. To decrease the knowledge
barrier, more accessible resources need to be available for researchers and students. The current
information can be seen as confusing, non-specific, and difficult to find. The FDA could easily
understand quick fact sheets or a more comprehensive requirement list for innovators to
reference. The information for innovation is not placed together on the website. The interviewees
explained how information was hard to find or confusing to understand; hence, why multiple
project owners began companies with paid experts.
To address the lack of information and guidance, more grants could be created by the
FDA to have specialists visit universities. Another idea is to offer guest lectures to universities
by compliance specialists. Often, students and researchers are wary of reaching out to the FDA
first. To address this problem, the FDA could develop a program to reach out about compliance
efforts first or creating an inquiry box on their website.
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